Is a mass immunization program for pandemic (H1N1) 2009 good value for money?  
Evidence from the Canadian experience  

Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M

Record Status  
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details  

DOI  
10.1016/j.vaccine.2010.07.010

Indexing Status  
Subject indexing assigned by NLM

MeSH  
Cost-Benefit Analysis; Disease Outbreaks /prevention & control; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines /economics; Influenza, Human /prevention & control; Mass Vaccination /economics; Models, Economic; Ontario; Sensitivity and Specificity

AccessionNumber  
22010001624

Date bibliographic record published  
09/03/2011